-
Is ibrutinib-related atrial fibrillation dose dependent? Insights from an individual case level analysis of the World Health Organization pharmacovigilance database Leukemia (IF 12.8) Pub Date : 2024-09-19 Joachim Alexandre, Jonaz Font, Da-Silva Angélique, Baptiste Delapierre, Ghandi Damaj, Anne-Flore Plane, Damien Legallois, Paul Milliez, Charles Dolladille, Basile Chrétien
-
Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients J. Hematol. Oncol. (IF 29.5) Pub Date : 2024-09-19 Alcantara Marion, Chevrier Marion, Jardin Fabrice, Schmitt Anna, Houillier Caroline, Oberic Lucie, Chinot Olivier, Morschhauser Franck, Peyrade Frédéric, Houot Roch, Hoang-Xuan Khê, Ghesquieres Hervé, Soussain Carole
Results of conventional induction chemotherapies in primary central nervous system lymphoma (PCNSL) need to be improved. Ibrutinib, a BTK inhibitor, and lenalidomide, an immunomodulatory drug, have shown promising results at relapse, supporting to further assess their individual use in combination with high-dose methotrexate-based chemotherapy. Patients with newly diagnosed PCNSL were randomized to
-
Characterization of MYC Rearrangements in Multiple Myeloma: an Optical Genome Mapping Approach Blood Cancer J. (IF 12.9) Pub Date : 2024-09-20 Jung Yoon, Taesung Jeon, Jung-Ah Kwon, Soo-Young Yoon
-
Rates of Strokes in Californians with Sickle Cell Disease in the Post-STOP Era. Blood (IF 21.0) Pub Date : 2024-09-20 Olubusola B Oluwole,Ann Brunson,Oyebimpe Oluyemisi Adesina,Shaina Willen,Theresa Hm Keegan,Kleber Yotsumoto Fertrin,Ted Wun
Neurovascular complications, including strokes and transient ischemic attacks (TIAs), are common and cause significant morbidity in individuals with sickle cell disease (SCD). The STOP trial (1998) established chronic transfusions as the standard of care for children with SCD at high risk for stroke. Using statewide emergency department and hospitalization data from the California Department of Health
-
Efficient combinatorial adaptor-mediated targeting of acute myeloid leukemia with CAR T-cells Leukemia (IF 12.8) Pub Date : 2024-09-18 Laura Volta, Renier Myburgh, Christian Pellegrino, Christian Koch, Monique Maurer, Francesco Manfredi, Mara Hofstetter, Anne Kaiser, Florin Schneiter, Jan Müller, Marco M. Buehler, Roberto De Luca, Nicholas Favalli, Chiara F. Magnani, Timm Schroeder, Dario Neri, Markus G. Manz
-
Selective degradation of mutant FMS-like tyrosine kinase-3 requires BIM-dependent depletion of heat shock proteins Leukemia (IF 12.8) Pub Date : 2024-09-17 Melisa Halilovic, Mohamed Abdelsalam, Joanna Zabkiewicz, Michelle Lazenby, Caroline Alvares, Matthias Schmidt, Walburgis Brenner, Sara Najafi, Ina Oehme, Christoph Hieber, Yanira Zeyn, Matthias Bros, Wolfgang Sippl, Oliver H. Krämer
-
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy Leukemia (IF 12.8) Pub Date : 2024-09-17 Andrew J. Innes, Chloe Hayden, Victoria Orovboni, Simone Claudiani, Fiona Fernando, Afzal Khan, David Rees, Jennifer Byrne, Paolo Gallipoli, Sebastian Francis, Mhairi Copland, Gillian Horne, Manoj Raghavan, Claire Arnold, Angela Collins, Tanya Cranfield, Nicholas Cunningham, Akila Danga, Peter Forsyth, Rebecca Frewin, Paula Garland, Guy Hannah, Daniele Avenoso, Sandra Hassan, Brian J. P. Huntly, Jissan
-
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2024-09-19 Malin Hultcrantz, Hani Hassoun, Neha Korde, Kylee MacLachlan, Sham Mailankody, Dhwani Patel, Urvi A. Shah, Carlyn Rose Tan, David J. Chung, Oscar B. Lahoud, Heather J. Landau, Michael Scordo, Gunjan L. Shah, Sergio A. Giralt, Matthew J. Pianko, Miranda Burge, Kelly Barnett, Meghan Salcedo, Julia Caple, Linh Tran, Jenna Blaslov, Tala Shekarkhand, Selena Hamid, David Nemirovsky, Andriy Derkach, Oluwatobi
-
Current status and research directions in acute myeloid leukemia Blood Cancer J. (IF 12.9) Pub Date : 2024-09-19 Hagop Kantarjian, Gautam Borthakur, Naval Daver, Courtney D. DiNardo, Ghayas Issa, Elias Jabbour, Tapan Kadia, Koji Sasaki, Nicholas J. Short, Musa Yilmaz, Farhad Ravandi
-
Not so natural, not so killers. Blood (IF 21.0) Pub Date : 2024-09-19 Bruno Paiva,José-Angel Martinez-Climent
-
Susceptibility to BK polyomavirus-associated hemorrhagic cystitis in children undergoing allogeneic transplant. Haematologica (IF 8.2) Pub Date : 2024-09-19 Sheyar Abdullah,Anthony Sabulski,Zahra Hudda,Assem Ziady,Nathan Luebbering,Lucy Giordullo,Elizabeth Odegard,Jason T Blackard,Steve Kleiboeker,Michelle Altrich,Sonata Jodele,Alix E Seif,Stella M Davies,Benjamin L Laskin
Not available.
-
Comment to "Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma": chimeric antigen receptor T-cell therapy remains effective after exposure to bispecific antibodies. Haematologica (IF 8.2) Pub Date : 2024-09-19 Gilles Crochet,Roch Houot
Not available.
-
Management of iron overload: lessons from transfusion-dependent hemoglobinopathies. Blood (IF 21.0) Pub Date : 2024-09-18 Thomas D Coates
Prior to the advent of effective iron chelation, death from iron-induced cardiomyopathy and endocrine failure occurred in the second decade in patients with thalassemia major and this experience has driven expectation of poor outcomes and caused anxiety in all disorders associated with iron loading to this day. To be clear, severe iron overload still causes significant morbidity and mortality in many
-
Hemoglobin-based Transfusion Strategies for Cardiovascular - and Other Diseases: Restrictive, Liberal, or Neither? Blood (IF 21.0) Pub Date : 2024-09-18 Charles Natanson,Willard N Applefeld,Harvey G Klein
A "restrictive" red blood cell transfusion threshold, hemoglobin concentration <7-8 g/dL, has long been recommended for most hospitalized patients including anemic patients with stable cardiovascular disease (CVD). Although no threshold recommendation is given for acute coronary syndromes (ACS), recent evidence suggests that "liberal" rather than "restrictive" transfusion strategies are associated
-
Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma. Blood (IF 21.0) Pub Date : 2024-09-18 Noemi Puig,Cristina Agullo Roca,Teresa Contreras Sanfeliciano,M Teresa Cedena,Joaquín Martínez-López,Albert Oriol,María-Jesús Blanchard,Rafael Ríos-Tamayo,Belén Iñigo Rodríguez,Anna Sureda,Sunil Lakhwani,Javier de la Rubia Comos,Veronica Gonzalez-Calle,Valentín Cabañas,Luis Palomera,José María M Moraleda,Joan Bargay,Sergio Castro,Laura Rosiñol,Joan Bladé,Jesús F San-Miguel,Juan-Jose Lahuerta,Bruno
Quantitative immuneprecipitation mass-spectrometry (QIP-MS) allows the identification of the M-protein in patients with multiple myeloma (MM) otherwise in complete response, and could be considered suitable for measurable residual disease (MRD) evaluation in peripheral blood. In the context of the GEM2012MENOS65 and GEM2014MAIN trials, we compared the performance of QIP-MS in serum with next-generation
-
FDA IDE validation of multiple myeloma MRD test by flow cytometry Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-18 Dragan Jevremovic, Min Shi, Pedro Horna, Gregory E. Otteson, Michael M. Timm, Shannon A. Bennett, Linda B. Baughn, Patricia T. Greipp, Wilson I. Gonsalves, Prashant Kapoor, Morie A. Gertz, Moritz Binder, Francis K. Buadi, Angela Dispenzieri, Taxiarchis Kourelis, Eli Muchtar, Jiehao Zhou, S. Vincent Rajkumar, Shaji K. Kumar, Horatiu Olteanu
Two recent decisions by the Food and Drug Administration will likely significantly impact testing for multiple myeloma (MM) minimal residual disease (MRD). First, on April 12, 2024, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted to approve the use of MRD as an end point for accelerated approval of new treatments for patients with MM.1 This was a result of near 10 years effort by multiple
-
The importance of autologous stem cell transplantation in improving outcomes in newly diagnosed patients with multiple myeloma Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-18 Morie A. Gertz
CONFLICT OF INTEREST STATEMENT The author declares no conflict of interest.
-
Triplet therapy for advanced BCR::ABL1 positive myeloid leukaemias. Lancet Haematol. (IF 15.4) Pub Date : 2024-09-17 Mhairi Copland
-
Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. Lancet Haematol. (IF 15.4) Pub Date : 2024-09-17 Nicholas J Short,Daniel Nguyen,Elias Jabbour,Jayastu Senapati,Zhihong Zeng,Ghayas C Issa,Hussein Abbas,Cedric Nasnas,Wei Qiao,Xuelin Huang,Gautam Borthakur,Kelly Chien,Fadi G Haddad,Naveen Pemmaraju,Omer S Karrar,Danielle Nguyen,Marina Konopleva,Hagop Kantarjian,Farhad Ravandi
BACKGROUND Advanced phase Philadelphia chromosome-positive myeloid disease-consisting of chronic myeloid leukaemia in the myeloid blast phase and in the accelerated phase, and Philadelphia chromosome-positive acute myeloid leukaemia-is associated with poor outcomes. Although previous studies have suggested the benefit of chemotherapy and BCR::ABL1 tyrosine kinase inhibitor combinations, the optimal
-
Clearance of pathogenic erythrocytes is maintained despite spleen dysfunction in children with sickle cell disease Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-17 Abdoulaye Sissoko, Astan Cissé, Clémence Duverdier, Mickaël Marin, Lucie Dumas, Sandra Manceau, Blandine Maître, Anita Eckly, Aurélie Fricot‐Monsinjon, Camille Roussel, Papa Alioune Ndour, Michael Dussiot, Safi Dokmak, Béatrice Aussilhou, Jeanne Dembinski, Alain Sauvanet, François Paye, Mickaël Lesurtel, Jérôme Cros, Dominique Wendum, Magali Tichit, David Hardy, Carmen Capito, Slimane Allali, Pierre
In children with sickle cell disease (SCD), splenectomy is immediately beneficial for acute sequestration crises and hypersplenism (ASSC/HyS) but portends a long‐term risk of asplenia‐related complications. We retrieved peripheral and splenic red blood cells (RBCs) from 17 SCD children/teenagers undergoing partial splenectomy for ASSC/HyS, 12 adult subjects without RBC‐related disease undergoing splenectomy
-
Comparison of prognostic scores according to WHO classification in 170 patients with advanced mastocytosis and C‐finding treated with midostaurin Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-17 Maël Heiblig, Clément Gourguechon, Philippe Guilpain, Cristina Bulai‐Livideanu, Stéphane Barete, Yannick Chantran, Julie Agopian, Fabienne Brenet, Patrice Dubreuil, Jérémie Lespinasse, Richard Lemal, Olivier Tournilhac, Louis Terriou, David Launay, Laurence Bouillet, Catharina Chatain, Ghandi Damaj, Thomas Ballul, Celine Greco, Laura Polivka, Laurent Frenzel, Cécile Meni, Hassiba Bouktit, Dina Benabou
-
White blood cell count levels are associated with inflammatory response and constitute independent outcome predictors in adult patients with acute myeloid leukemia aged <60 years Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-16 Michael Ozga, Deedra Nicolet, Krzysztof Mrózek, Christopher J. Walker, James S. Blachly, Jessica Kohlschmidt, Shelley Orwick, Andrew J. Carroll, Richard A. Larson, Jonathan E. Kolitz, Bayard L. Powell, Richard M. Stone, John C. Byrd, Ann-Kathrin Eisfeld, Alice S. Mims
Acute myeloid leukemia (AML) is a biologically and clinically heterogenous disease with diverse genetic abnormalities1-6 and a wide-ranging white blood cell counts (WBC) at diagnosis.1 The 2022 European LeukemiaNet (ELN) genetic-risk classification incorporates cytogenetic and selected molecular alterations to define Favorable, Intermediate, and Adverse genetic-risk groups providing valuable prognostic
-
The cognitive age in medicine: Artificial intelligence, large language models, and iterative intelligence Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-16 John Nosta
CONFLICT OF INTEREST STATEMENT The author declares no conflicts of interest.
-
Thrombotic thrombocytopenic purpura masquerading as Evans syndrome Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-16 Sarah E. Mudra, Kaleb Ardoin, Vanya Aggarwal, Garrett Diltz, Pedro E. Alcedo Andrade, Catherine M. Broome
1 CASE PRESENTATION A 26-year-old female with a history of chronic urticaria (treated with omalizumab in the past) and recently treated chlamydia trachomatis infection presented to an outside emergency department after a syncopal episode. She endorsed a three-day history of nausea, vomiting, fatigue, and ecchymoses. Initial laboratory analysis revealed macrocytic anemia (hemoglobin 4.6 g/dL) with a
-
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials Leukemia (IF 12.8) Pub Date : 2024-09-16 Mouhamad Khouja, Linmiao Jiang, Karol Pal, Peter James Stewart, Binaya Regmi, Martin Schwarz, Wolfram Klapper, Stefan K. Alig, Nikos Darzentas, Hanneke C. Kluin-Nelemans, Olivier Hermine, Martin Dreyling, David Gonzalez de Castro, Eva Hoster, Christiane Pott
-
Potent combination benefit of the AKT inhibitor capivasertib and the BCL-2 inhibitor venetoclax in diffuse large B cell lymphoma Leukemia (IF 12.8) Pub Date : 2024-09-16 Brandon S. Willis, Kevin Mongeon, Hannah Dry, India L. Neveras, Nadezda Bryan, Meghana Pandya, Justine Roderick-Richardson, Wendan Xu, Li Yang, Alan Rosen, Corinne Reimer, Liliana Tuskova, Pavel Klener, Jerome T. Mettetal, Georg Lenz, Simon T. Barry
-
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia J. Hematol. Oncol. (IF 29.5) Pub Date : 2024-09-16 David Sedloev, Qian Chen, Julia M. Unglaub, Nicola Schanda, Yao Hao, Eleni Besiridou, Brigitte Neuber, Anita Schmitt, Simon Raffel, Yi Liu, Maike Janssen, Carsten Müller-Tidow, Michael Schmitt, Tim Sauer
Relapsed and refractory acute myeloid leukemia (AML) carries a dismal prognosis. CAR T cells have shown limited efficacy in AML, partially due to dysfunctional autologous T cells and the extended time for generation of patient specific CAR T cells. Allogeneic NK cell therapy is a promising alternative, but strategies to enhance efficacy and persistence may be necessary. Proteasome inhibitors (PI) induce
-
Synergistic effect of FMS-like tyrosine kinase-3 (FLT3) inhibitors combined with a CDK7 inhibitor in FLT3-ITD-mutated acute myeloid leukemia Blood Cancer J. (IF 12.9) Pub Date : 2024-09-16 Bon-Kwan Koo, Eun-Ji Choi, Ju Hyun Moon, Ji Yun Kim, Hyunkyung Park, Han-Seung Park, Yunsuk Choi, Jung-Hee Lee, Kyoo-Hyung Lee, Eun Kyung Choi, Eunji Kim, Je-Hwan Lee, Eun-Hye Hur
-
Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia Blood Cancer J. (IF 12.9) Pub Date : 2024-09-16 Yu Liu, Wenbing Liu, Anli Lai, Yihan Mei, Ying Wang, Hui Wei, Qing Rao, Runxia Gu, Yingchang Mi, Min Wang, Jianxiang Wang, Shaowei Qiu
-
Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy Blood Cancer J. (IF 12.9) Pub Date : 2024-09-16 Sophia Gross, Jana Ihlow, Leonie Busack, Kacper Adamiak, Jens Schrezenmeier, Julia Jesse, Michaela Schwarz, Anne Flörcken, Lam Giang Vuong, Kathrin Rieger, Jan Krönke, Philipp le Coutre, Vivien Boldt, Ann-Christin von Brünneck, David Horst, Thomas Burmeister, Igor-Wolfgang Blau, Ulrich Keller, Lars Bullinger, Jörg Westermann
-
HDAC7 is a potential therapeutic target in acute erythroid leukemia Leukemia (IF 12.8) Pub Date : 2024-09-15 Wenyu Zhang, Keita Yamamoto, Yu-Hsuan Chang, Tomohiro Yabushita, Yangying Hao, Ruka Shimura, Jakushin Nakahara, Shiori Shikata, Kohei Iida, Qianyi Chen, Xichen Zhang, Toshio Kitamura, Susumu Goyama
-
Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting J. Hematol. Oncol. (IF 29.5) Pub Date : 2024-09-13 Di Liu, Leilei Wu, Xiaoling Xu, Shuangyan Yang, Ming Liu, Min Hu, Shengxiang Ren, Yaping Xu
Combination of immunotherapy with radiotherapy is under active investigation. The PACIFIC trial firmly established the treatment paradigm of consolidation immunotherapy following definitive chemoradiotherapy, inspiring a series of similar or exploratory combination regimens. This summary highlighted six reports updated in the 2024 ASCO Annual Meeting.
-
c-Myc alone is enough to reprogram fibroblasts into functional macrophages J. Hematol. Oncol. (IF 29.5) Pub Date : 2024-09-12 Shanshan Li, Guoyu Chen, Xia Huang, Yingwen Zhang, Shuhong Shen, Haizhong Feng, Yanxin Li
Macrophage-based cell therapy is promising in solid tumors, but the efficient acquisition of macrophages remains a challenge. Induced pluripotent stem cell (iPSC)-induced macrophages are a valuable source, but time-consuming and costly. The application of reprogramming technologies allows for the generation of macrophages from somatic cells, thereby facilitating the advancement of cell-based therapies
-
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in transplant-eligible patients Blood Cancer J. (IF 12.9) Pub Date : 2024-09-13 Nisha S. Joseph, Jonathan L. Kaufman, Vilas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Lawrence H. Boise, Sara M. DiCamillo, Danielle Roberts, Ajay K. Nooka, Sagar Lonial
-
Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myélodysplasies (GFM) study Leukemia (IF 12.8) Pub Date : 2024-09-12 Florence Rabian, Sylvie Chevret, Bérengère Gruson, Sylvain Thépot, Anouk Walter-Petrich, Thorsten Braun, Norbert Vey, José Miguel Torregrosa-Diaz, Pierre Peterlin, Andrea Toma, Maud D’Aveni, Jacques Delaunay, Laurence Legros, Nathalie Droin, Fatiha Chermat, Daniel Lusina, Lionel Adès, Rosa Sapena, Eric Solary, Pierre Fenaux, Raphael Itzykson
-
USP4 regulates ribosome biogenesis and protein synthesis for hematopoietic stem cell regeneration and leukemia progression Leukemia (IF 12.8) Pub Date : 2024-09-12 Bo Liu, Xianli Zhang, Yuanyuan Zhou, Haiping Liu, Zhenkun Wang, Yuting Fu, Qiongdan Gao, Xiang Cheng, Qingyuan Sun, Zhenyu Ju
-
Bispecific antibodies in the treatment of multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2024-09-12 Anup Joseph Devasia, Ajai Chari, Guido Lancman
-
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma Blood Cancer J. (IF 12.9) Pub Date : 2024-09-12 Carolien C. H. M. Maas, David van Klaveren, Müjde Durmaz, Otto Visser, Djamila E. Issa, Eduardus F. M. Posthuma, Josée M. Zijlstra, Martine E. D. Chamuleau, Pieternella J. Lugtenburg, Marie José Kersten, Avinash G. Dinmohamed
-
-
Therapy response in AML: a tale of two T cells Blood (IF 21.0) Pub Date : 2024-09-12 Livius Penter, Catherine J. Wu
-
-
-
A menin-KMT2A inhibitor to overcome resistance Blood (IF 21.0) Pub Date : 2024-09-12 Caroline A. Heckman
-
Typhoidal cells: unraveling the diagnostic conundrum in brucellosis instead Blood (IF 21.0) Pub Date : 2024-09-12 Ruimin Li, Xiaoqiang Lian
-
Anti-CD37 CAR T cells: another arrow in the quiver Blood (IF 21.0) Pub Date : 2024-09-12 Dimitrios Mougiakakos
-
Selective targeting of mutated calreticulin by the monoclonal antibody INCA033989 inhibits oncogenic function of MPN Blood (IF 21.0) Pub Date : 2024-09-12 Edimara S. Reis, Rebecca Buonpane, Hamza Celik, Caroline Marty, Angela Lei, Fatoumata Jobe, Mark Rupar, Yue Zhang, Darlise DiMatteo, Rahel Awdew, Bianca L. Ferreira, Lynn Leffet, Lu Lu, Elodie Rosa, Maxime Evrard, Gaurang Trivedi, Brittney Wass, April Horsey, Xin He, Maryanne Covington, Alla Volgina, Florence Pasquier, Laurence Legros, Guillemette Fouquet, William Vainchenker, Yan-ou Yang, Breann Barker
Mutations in calreticulin (mutCALR) are the second most common drivers of myeloproliferative neoplasms (MPNs) and yet, the current therapeutic landscape lacks a selective agent for mutCALR-expressing MPNs. Here, we show that the monoclonal antibody INCA033989 selectively targets mutCALR-positive cells. INCA033989 antagonized mutCALR-driven signaling and proliferation in engineered cell lines and primary
-
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis Blood (IF 21.0) Pub Date : 2024-09-12 Brooj Abro, Matthew J. Maurer, Thomas M. Habermann, W. Richard Burack, Jennifer R. Chapman, Jonathon B. Cohen, Jonathan W. Friedberg, Giorgio Inghirami, Brad S. Kahl, Melissa C. Larson, Brian K. Link, Izidore S. Lossos, Peter Martin, Timothy J. McDonnell, Loretta J. Nastoupil, Shaun M. Riska, Sergei Syrbu, Francisco Vega, Kiran R. Vij, Christopher R. Flowers, James R. Cerhan, David L. Jaye, Andrew
Recent introduction of 2 different lymphoma classifications has raised concerns about consistency in diagnosis, management, and clinical trial enrollment. Data from a large cohort reflecting real-world clinical practice suggest that differences between the classifications will affect <1% of non-Hodgkin lymphomas.
-
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in adults older than age 70 years Blood (IF 21.0) Pub Date : 2024-09-12 Roland B. Walter, Victoria Potter, Charles Craddock
The advent of reduced-intensity conditioning regimens, improvements in graft-versus-host disease prophylaxis, and better supportive care have permitted increasing use of allogeneic hematopoietic cell transplantation (allo-HCT) in adults aged ≥70 years with acute myeloid leukemia. However, although potentially curative, nonrelapse mortality and relapse represent the main causes of treatment failure
-
Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma Blood (IF 21.0) Pub Date : 2024-09-12 Katie Maurer, Isabella N. Grabski, Roch Houot, Satyen H. Gohil, Shogo Miura, Robert Redd, Haoxiang Lyu, Wesley Lu, Yohei Arihara, Justin Budka, Mikaela McDonough, Michela Ansuinelli, Carol Reynolds, Heather Jacene, Shuqiang Li, Kenneth J. Livak, Jerome Ritz, Brodie Miles, Mike Mattie, Donna S. Neuberg, Rafael A. Irizarry, Philippe Armand, Catherine J. Wu, Caron Jacobson
Engineered cellular therapy with CD19-targeting chimeric antigen receptor T cells (CAR-Ts) has revolutionized outcomes for patients with relapsed/refractory large B-cell lymphoma (LBCL), but the cellular and molecular features associated with response remain largely unresolved. We analyzed serial peripheral blood samples ranging from the day of apheresis (day –28/baseline) to 28 days after CAR-T infusion
-
Cybersecurity and the blood supply: The vulnerabilities of the technological revolution Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-12 Jeremy W. Jacobs, Nicole De Simone, Miriam Andrea Duque, Yanyun Wu, Dawn C. Ward, Jennifer S. Woo, Laura D. Stephens, Elizabeth S. Allen, Mandy F. O'Leary, Sheharyar Raza, Garrett S. Booth, Brian D. Adkins
CONFLICT OF INTEREST STATEMENT The authors declare no conflicts of interest.
-
Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with transfusion‐dependent β‐thalassemia Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-12 Daniele Lello Panzieri, Dario Consonni, Natalia Scaramellini, Guido Ausenda, Francesca Granata, Nancy Caponio, Lorena Duca, Simona Leoni, Silvia Elli, Marta Ferraresi, Vittorio Bolis, Cristina Curcio, Milena Agata Irrera, Diletta Maira, Giovanna Graziadei, Elena Cassinerio, Maria Domenica Cappellini, Rayan Bou‐Fakhredin, Valentina Brancaleoni, Irene Motta
Luspatercept is the first erythropoiesis-modulating agent approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treating anemia in adult transfusion-dependent β-thalassemia (TDT) patients. As observed in clinical trials1 and real-life experience,2 response to luspatercept in TDT is heterogeneous. It can range from patients who do not respond to those who become
-
CXCR4 as a therapeutic target in acute myeloid leukemia Leukemia (IF 12.8) Pub Date : 2024-09-11 Jan Korbecki, Mateusz Bosiacki, Patrycja Kupnicka, Katarzyna Barczak, Dariusz Chlubek, Irena Baranowska-Bosiacka
-
Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children’s Oncology Group study Leukemia (IF 12.8) Pub Date : 2024-09-11 Susan R. Rheingold, Deepa Bhojwani, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, John A. Kairalla, Mary Shago, Nyla A. Heerema, Andrew J. Carroll, Heather Breidenbach, Michael Borowitz, Brent L. Wood, Anne L. Angiolillo, Barbara L. Asselin, W. Paul Bowman, Patrick Brown, ZoAnn E. Dreyer, Kimberly P. Dunsmore, Joanne M. Hilden, Eric Larsen, Kelly Maloney, Yousif Matloub, Leonard A. Mattano, Stuart S. Winter
-
The non-canonical BAF chromatin remodeling complex is a novel target of spliceosome dysregulation in SF3B1-mutated chronic lymphocytic leukemia Leukemia (IF 12.8) Pub Date : 2024-09-11 Daniel Hägerstrand, Blaž Oder, Diego Cortese, Ying Qu, Amrei Binzer-Panchal, Cecilia Österholm, Teresa Del Peso Santos, Leily Rabbani, Hassan Foroughi Asl, Aron Skaftason, Viktor Ljungström, August Lundholm, Maria Koutroumani, Zahra Haider, Cecilia Jylhä, John Mollstedt, Larry Mansouri, Karla Plevova, Andreas Agathangelidis, Lydia Scarfò, Marine Armand, Alice F. Muggen, Neil E. Kay, Tait Shanafelt
-
Outcome after short exposure to tyrosine kinase inhibitors in pregnant female patients with chronic myeloid leukemia J. Hematol. Oncol. (IF 29.5) Pub Date : 2024-09-11 Yingling Zu, Huifang Zhao, Jianling Chen, Huibing Dang, Yanrong Shi, Lixin Liang, Shuhao Mei, Yongping Song, Yanli Zhang
Unintended pregnancy for female patients with chronic myeloid leukemia (CML) raises the discussion of treatment choices due to the teratogenicity of tyrosine kinase inhibitor (TKI). We report 51 accidental pregnant CML chronic phase (CP) patients with TKI withdrawal immediately after pregnancy from December 2010 to February 2024 to observe the effect of short exposure to TKI on the fetus and the infant
-
Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial Blood Cancer J. (IF 12.9) Pub Date : 2024-09-11 Arleigh McCurdy, Donna Reece, Martha L. Louzada, Darrell White, Stephen Parkin, Michael P. Chu, Rami Kotb, Hira Mian, Ibraheem Othman, Jiandong Su, Aniba Khan, Engin Gul, Suzanne Trudel
-
Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2024-09-11 Marietheres Evers, Thorsten Stühmer, Martin Schreder, Torsten Steinbrunn, Martina Rudelius, Franziska Jundt, Regina Ebert, Tanja Nicole Hartmann, Ralf Christian Bargou, Andreas Rosenwald, Ellen Leich
-
Machine‐learning based subgroups of AL amyloidosis and cumulative incidence of mortality and end stage kidney disease Am. J. Hematol. (IF 10.1) Pub Date : 2024-09-11 Shankara K. Anand, Andrew Staron, Lisa M. Mendelson, Tracy Joshi, Natasha Burke, Vaishali Sanchorawala, Ashish Verma
Immunoglobulin light chain (AL) amyloidosis is a multisystem disease with varied treatment options and disease‐related outcomes. Current staging systems rely on a limited number of cardiac, renal, and plasma cell dyscrasia biomarkers. To improve prognostication for all‐cause mortality and end‐stage kidney disease (ESKD), we applied unsupervised machine learning using a comprehensive set of clinical
-
Diverse mechanisms of leukemogenesis associated with PAX5 germline mutation Leukemia (IF 12.8) Pub Date : 2024-09-10 Laura Rachele Bettini, Grazia Fazio, Claudia Saitta, Rocco Piazza, Sonia Palamini, Chiara Buracchi, Stefano Rebellato, Nicola Santoro, Cristiano Simone, Andrea Biondi, Giovanni Cazzaniga
-
Are measurable residual disease results after consolidation therapy useful in children with acute lymphoblastic leukemia? Leukemia (IF 12.8) Pub Date : 2024-09-10 Janine Stutterheim, Rachella van der Waarden, Hester A. de Groot-Kruseman, Edwin Sonneveld, Valérie de Haas, Rana Dandis, C. Ellen van der Schoot, Vincent H. J. van der Velden, Rob Pieters